Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. - Wikidata - awgldk - TriplyDB

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

http://www.wikidata.org/entity/Q36162494

about

Targeting the Checkpoint to Kill Cancer Cells Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Drosophila Cancer Models Identify Functional Differences between Ret Fusions.Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1 Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.Translational and clinical implications of the genetic landscape of prostate cancer.Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.AZD1775 Induces Toxicity Through Double-Stranded DNA Breaks Independently of Chemotherapeutic Agents in p53-Mutated Colorectal Cancer Cells.Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.Expression and clinical significance of Wee1 in colorectal cancer.Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma.Unravelling the biology of SCLC: implications for therapy.Cytokinetic effects of Wee1 disruption in pancreatic cancer.Investigational drugs for head and neck cancer.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.Cell Cycle Regulation and Melanoma.The cell cycle checkpoint inhibitors in the treatment of leukemias.Small cell lung cancer: Time to revisit DNA-damaging chemotherapy.HPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma.Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes.Advances of small molecule targeting of kinases.Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastases.Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

P2860

Q26795781-976F87DD-85E6-4674-ADE4-05BD948C17C6 Q28066320-D3B92E13-D4B3-4573-AAA6-1FB1234DF22E Q28066904-ADF9740B-466C-4A46-B371-FC243F5DD5F7 Q28078268-18E66D0F-2A04-40FD-9637-8E2A5A1295CA Q28833606-C50E9EF0-8505-47F3-B56E-66AC97631249 Q33798999-07059D6B-223B-4D34-A2E5-8DF67F21CF3D Q36132331-6183EEB4-3047-4601-A0D1-A09107B099ED Q36309585-67CC44C7-146F-4497-873D-651D6E1BDED9 Q36546455-579C2AA0-1CD3-4DBF-83AF-2158B02BECBD Q36811784-1833587F-E150-4E04-B17E-38C36855EED8 Q36843733-26262454-416A-4C05-9914-17A189007E5A Q36956909-702B86E0-75EB-42C7-A795-1C75879096DF Q37158437-D1745346-039D-410C-82F6-A32CC8BADE03 Q37270512-710AA2FD-8320-4F77-8008-43E40538C0BF Q37376481-CD038CC8-C2D1-4097-82F4-9F7BEB7E6C40 Q37580332-6B799CDC-4C18-4851-A347-87D72FCBD8BE Q37634102-00990AC8-6CCB-473E-8D81-2D04C3479F01 Q38261022-06DD983C-573A-4871-AEE6-FA8A34065A16 Q38631373-3AADD966-118E-4D22-9E8D-4EEFBAA13A23 Q38712184-A1B82D4A-2D45-44DD-87D4-23F9EBE811E4 Q38719309-063C78D6-71DA-4040-AFDA-225A6BD72489 Q38723383-49003930-C7A5-4423-BB2B-19B538AE7DDE Q38737092-88D4F27F-7887-40AF-980A-72846B102401 Q38763225-9DE33F13-4535-42CB-8FE3-64AC1FB5724E Q38769421-B26E1A9E-7050-4722-9AF0-3DD33197960B Q38793178-EAE5E545-A2B2-4082-897A-0A554FAF2FAB Q38800788-2D6C86ED-BAA9-4D5B-A4CE-E44E2B7000F2 Q38806371-D142A1D7-7C66-4910-A2E7-5508C8187AAA Q38815527-6ACE0A77-7610-409B-8BAB-B75FC103F6DD Q38868502-E52DC483-2B14-4A29-A18E-CE98AB9B8EDB Q38888068-E83AB705-C59C-4140-A8C8-F966E18F8F72 Q39020753-67C5CEC4-45B7-4C85-96DC-F19BAD43A9A6 Q39142273-990B42A8-7ED9-4003-ACD2-B4EA9EB92B95 Q39186868-08877A8F-C2A3-4FE2-AF4F-91AE0166CA08 Q39450797-146A6C6E-177F-47ED-B22D-1AC6CCF5A490 Q40180908-27AC183B-273D-4317-973B-4CB99BCECC1B Q41063971-9037EE16-A899-4566-AE97-9569B0BC6094 Q41851539-45B16C59-6E0A-4830-A3CF-3E7E486B457F Q42366556-AE5D7442-A8E5-4DC0-8A41-30AC39C6CBBE Q46063736-1783C409-9897-4D26-9B3E-49D56C4F7856

P2860

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

http://www.wikidata.org/entity/Q36162494

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Phase I Study of Single-Agent ...... With Refractory Solid Tumors.

@ast

Phase I Study of Single-Agent ...... With Refractory Solid Tumors.

@en

type

label

Phase I Study of Single-Agent ...... With Refractory Solid Tumors.

@ast

Phase I Study of Single-Agent ...... With Refractory Solid Tumors.

@en

prefLabel

Phase I Study of Single-Agent ...... With Refractory Solid Tumors.

@ast

Phase I Study of Single-Agent ...... With Refractory Solid Tumors.

@en

P1433

Q36162494-4A3C682A-25C7-4075-9758-CC67C42A586F

P1476

Q36162494-7F22FE43-0FA5-4144-8CAB-34C4B441AB4B

P2093

Q36162494-09FD64B9-942F-4262-B8EA-DDBFF99046AE

Q36162494-110D20E7-F089-487F-9E33-82CF7B5D167D

Q36162494-1519B001-3E34-49DF-A0FC-0B81B414A125

Q36162494-2284DA6D-286B-4C9D-87DD-47B7237E4285

Q36162494-3AC8BE6C-019C-468C-95AC-200F46B58DA5

Q36162494-3CBC86D6-2450-4ED3-8054-8E49225F66E5

Q36162494-658F4593-7989-4AF4-98D0-CA8599C98C5A

Q36162494-70F0F814-C849-4D56-968E-BFE585AF34C5

Q36162494-A2FA2A86-B4B8-40B9-9DCB-444AA9CB7345

Q36162494-D4359762-B5B9-41E4-B3FE-9B860B770783

P2860

Q36162494-01659980-5A97-4758-B64C-7F5FA832198D

Q36162494-15503D4D-7E41-4BB5-978F-E6FDAA76E8D0

Q36162494-1B9CD0EE-8B51-4DB3-8DD7-8FBEBF27C0E2

Q36162494-2997686F-D718-4D38-BB44-5C9AA475F3EA

Q36162494-3F42AAEA-BC5A-4168-8D4A-CB841E53D074

Q36162494-4AAF180E-F5AC-4E63-A522-EBEFE14DF3A8

Q36162494-4C6AEE41-0A91-48DF-B06D-099C7C109600

Q36162494-4F5557D2-0859-4512-AA35-5D3785C8F526

Q36162494-5BFF433A-58D4-46CF-A7B8-274A658DDAE2

Q36162494-6AA0235D-FE79-4428-8201-514B22AD5FD7

P304

Q36162494-CB909E07-6796-4F0F-974F-C52577B0A770

P31

Q36162494-44F93A2B-E00D-4617-8444-DC35CC364AB1

P356

Q36162494-784863E5-6D49-4D4A-93A3-216A0234AEC1

P407

Q36162494-5EAFA4C9-583D-4BCE-A575-651344129A49

P433

Q36162494-68057B36-2D1D-47D1-8060-567A9B61959B

P478

Q36162494-0401F4A4-AF15-4837-94F2-234A17FF593C

P577

Q36162494-0B017037-348C-4BBC-B7EE-98582673B6CF

P698

Q36162494-4FFD4AE7-C217-4DC4-992C-5AB725F1992C

P921

Q36162494-31B15F0C-2F35-4483-BAA8-DF69F667EB1F

P932

Q36162494-9A9766E6-8B1F-472C-B85F-38AAD9887430

P356

JCO.2014.60.4009

P1433

Journal of Clinical Oncology

P1476

Phase I Study of Single-Agent ...... With Refractory Solid Tumors.

@en

P2093

Alice P Chen

http://www.w3.org/2001/XMLSchema#string

Deborah Wilsker

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Jennifer Zlott

http://www.w3.org/2001/XMLSchema#string

Jerry Collins

http://www.w3.org/2001/XMLSchema#string

Jiuping Ji

http://www.w3.org/2001/XMLSchema#string

Khanh Do

http://www.w3.org/2001/XMLSchema#string

Robert J Kinders

http://www.w3.org/2001/XMLSchema#string

Shivaani Kummar

http://www.w3.org/2001/XMLSchema#string

Tomoko Freshwater

http://www.w3.org/2001/XMLSchema#string

P2860

The BRCT domain is a phospho-protein binding domain

Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation

Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle

STRUCTURE-FUNCTION OF THE TUMOR SUPPRESSOR BRCA1

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Raptor is phosphorylated by cdc2 during mitosis.

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts

P304

3409-3415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.60.4009

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25964244

http://www.w3.org/2001/XMLSchema#string

P921

P932

4606059

http://www.w3.org/2001/XMLSchema#string